GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

GSK’s Vi­iV Health­care is eye­ing 2026 and 2027 for po­ten­tial longer-act­ing ver­sions of its re­spec­tive HIV in­jecta­bles for pre­ven­tion and treat­ment, ex­ec­u­tives said on a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER